Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration

Twenty-four week results of an uncontrolled, prospective cohort study

Wolfgang Geitzenauer, Stephan Michels, Franz Prager, Philip J Rosenfeld, Gabriela Kornek, Laurenz Vormittag, Ursula Schmidt-Erfurth

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND: To compare safety, visual acuity (VA), and anatomic outcomes of 2.5 mg/kg and 5 mg/kg intravenous bevacizumab in patients with neovascular age-related macular degeneration. METHODS: In an institutional cohort study, 16 patients (2 cohorts, 27 eyes) with neovascular age-related macular degeneration were treated with 5 mg/kg intravenous bevacizumab and 2.5 mg/kg, respectively. All patients received 3 initial intravenous infusions at 2-week intervals. The main outcome measures were VA, optical coherence tomography, and fluorescein angiography. RESULTS: No serious systemic or ocular adverse events were identified. By Day 7, mean VA increased from 56 letters (20/80) at baseline to 60 letters (20/63) in the 5 mg/kg group and mean central retinal thickness decreased by 83 μm. In the 2.5 mg/kg group, mean VA increased from 55 letters (20/80) to 66 letters (20/50) and mean central retinal thickness decreased by 93 μm. By Month 3, VA improved by 10 letters compared to baseline in the 5 mg/kg group and by 9 letters in the 2.5 mg/kg group. Central retinal thickness was reduced by 128 μm in the 5 mg/kg group and by 127 μm in the 2.5 mg/kg group. These benefits were sustained through 6 months. No statistically significant difference was found between both treatment groups regarding safety, VA, and anatomic outcomes. CONCLUSION: Similar VA, optical coherence tomography, and angiographic improvements were observed in both treatment groups up to 6 months. Further follow-up is required to evaluate the long-term durability and safety of both treatment regimens.

Original languageEnglish
Pages (from-to)1375-1386
Number of pages12
JournalRetina
Volume28
Issue number10
DOIs
StatePublished - Nov 1 2008

Fingerprint

Macular Degeneration
Visual Acuity
Cohort Studies
Prospective Studies
Optical Coherence Tomography
Safety
Fluorescein Angiography
Bevacizumab
Intravenous Infusions
Therapeutics
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration : Twenty-four week results of an uncontrolled, prospective cohort study. / Geitzenauer, Wolfgang; Michels, Stephan; Prager, Franz; Rosenfeld, Philip J; Kornek, Gabriela; Vormittag, Laurenz; Schmidt-Erfurth, Ursula.

In: Retina, Vol. 28, No. 10, 01.11.2008, p. 1375-1386.

Research output: Contribution to journalArticle

Geitzenauer, Wolfgang ; Michels, Stephan ; Prager, Franz ; Rosenfeld, Philip J ; Kornek, Gabriela ; Vormittag, Laurenz ; Schmidt-Erfurth, Ursula. / Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration : Twenty-four week results of an uncontrolled, prospective cohort study. In: Retina. 2008 ; Vol. 28, No. 10. pp. 1375-1386.
@article{02a684cd8cdd49c4a4ca8ff65640d031,
title = "Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: Twenty-four week results of an uncontrolled, prospective cohort study",
abstract = "BACKGROUND: To compare safety, visual acuity (VA), and anatomic outcomes of 2.5 mg/kg and 5 mg/kg intravenous bevacizumab in patients with neovascular age-related macular degeneration. METHODS: In an institutional cohort study, 16 patients (2 cohorts, 27 eyes) with neovascular age-related macular degeneration were treated with 5 mg/kg intravenous bevacizumab and 2.5 mg/kg, respectively. All patients received 3 initial intravenous infusions at 2-week intervals. The main outcome measures were VA, optical coherence tomography, and fluorescein angiography. RESULTS: No serious systemic or ocular adverse events were identified. By Day 7, mean VA increased from 56 letters (20/80) at baseline to 60 letters (20/63) in the 5 mg/kg group and mean central retinal thickness decreased by 83 μm. In the 2.5 mg/kg group, mean VA increased from 55 letters (20/80) to 66 letters (20/50) and mean central retinal thickness decreased by 93 μm. By Month 3, VA improved by 10 letters compared to baseline in the 5 mg/kg group and by 9 letters in the 2.5 mg/kg group. Central retinal thickness was reduced by 128 μm in the 5 mg/kg group and by 127 μm in the 2.5 mg/kg group. These benefits were sustained through 6 months. No statistically significant difference was found between both treatment groups regarding safety, VA, and anatomic outcomes. CONCLUSION: Similar VA, optical coherence tomography, and angiographic improvements were observed in both treatment groups up to 6 months. Further follow-up is required to evaluate the long-term durability and safety of both treatment regimens.",
author = "Wolfgang Geitzenauer and Stephan Michels and Franz Prager and Rosenfeld, {Philip J} and Gabriela Kornek and Laurenz Vormittag and Ursula Schmidt-Erfurth",
year = "2008",
month = "11",
day = "1",
doi = "10.1097/IAE.0b013e3181863f96",
language = "English",
volume = "28",
pages = "1375--1386",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration

T2 - Twenty-four week results of an uncontrolled, prospective cohort study

AU - Geitzenauer, Wolfgang

AU - Michels, Stephan

AU - Prager, Franz

AU - Rosenfeld, Philip J

AU - Kornek, Gabriela

AU - Vormittag, Laurenz

AU - Schmidt-Erfurth, Ursula

PY - 2008/11/1

Y1 - 2008/11/1

N2 - BACKGROUND: To compare safety, visual acuity (VA), and anatomic outcomes of 2.5 mg/kg and 5 mg/kg intravenous bevacizumab in patients with neovascular age-related macular degeneration. METHODS: In an institutional cohort study, 16 patients (2 cohorts, 27 eyes) with neovascular age-related macular degeneration were treated with 5 mg/kg intravenous bevacizumab and 2.5 mg/kg, respectively. All patients received 3 initial intravenous infusions at 2-week intervals. The main outcome measures were VA, optical coherence tomography, and fluorescein angiography. RESULTS: No serious systemic or ocular adverse events were identified. By Day 7, mean VA increased from 56 letters (20/80) at baseline to 60 letters (20/63) in the 5 mg/kg group and mean central retinal thickness decreased by 83 μm. In the 2.5 mg/kg group, mean VA increased from 55 letters (20/80) to 66 letters (20/50) and mean central retinal thickness decreased by 93 μm. By Month 3, VA improved by 10 letters compared to baseline in the 5 mg/kg group and by 9 letters in the 2.5 mg/kg group. Central retinal thickness was reduced by 128 μm in the 5 mg/kg group and by 127 μm in the 2.5 mg/kg group. These benefits were sustained through 6 months. No statistically significant difference was found between both treatment groups regarding safety, VA, and anatomic outcomes. CONCLUSION: Similar VA, optical coherence tomography, and angiographic improvements were observed in both treatment groups up to 6 months. Further follow-up is required to evaluate the long-term durability and safety of both treatment regimens.

AB - BACKGROUND: To compare safety, visual acuity (VA), and anatomic outcomes of 2.5 mg/kg and 5 mg/kg intravenous bevacizumab in patients with neovascular age-related macular degeneration. METHODS: In an institutional cohort study, 16 patients (2 cohorts, 27 eyes) with neovascular age-related macular degeneration were treated with 5 mg/kg intravenous bevacizumab and 2.5 mg/kg, respectively. All patients received 3 initial intravenous infusions at 2-week intervals. The main outcome measures were VA, optical coherence tomography, and fluorescein angiography. RESULTS: No serious systemic or ocular adverse events were identified. By Day 7, mean VA increased from 56 letters (20/80) at baseline to 60 letters (20/63) in the 5 mg/kg group and mean central retinal thickness decreased by 83 μm. In the 2.5 mg/kg group, mean VA increased from 55 letters (20/80) to 66 letters (20/50) and mean central retinal thickness decreased by 93 μm. By Month 3, VA improved by 10 letters compared to baseline in the 5 mg/kg group and by 9 letters in the 2.5 mg/kg group. Central retinal thickness was reduced by 128 μm in the 5 mg/kg group and by 127 μm in the 2.5 mg/kg group. These benefits were sustained through 6 months. No statistically significant difference was found between both treatment groups regarding safety, VA, and anatomic outcomes. CONCLUSION: Similar VA, optical coherence tomography, and angiographic improvements were observed in both treatment groups up to 6 months. Further follow-up is required to evaluate the long-term durability and safety of both treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=58949085200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58949085200&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e3181863f96

DO - 10.1097/IAE.0b013e3181863f96

M3 - Article

VL - 28

SP - 1375

EP - 1386

JO - Retina

JF - Retina

SN - 0275-004X

IS - 10

ER -